Iovance Biotherapeutics is trading at $10.62, +4.17% on September 22, 2026, amid broader biotech-sector momentum.
- Biotech is up 2.07%, supported by positive clinical news and optimism around a potential $1 billion-plus AI drug-discovery collaboration.
- Recent record Amtagvi revenue and favorable analyst sentiment may be reinforcing the move, but are not fresh catalysts.
- No new company-specific announcement was identified during the session.